TQH-2929

N/A

Report date: 2026/03/31 20:00:21

Base Information

Drug NameTQH-2929
Drug Alias NameTQH2929TQH-2929
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionCytokine receptors antagonistsInterleukin-36 receptor inhibitors
TargetsCytokine receptorsInterleukin-36 receptor
Therapy Area/IndicationsGeneralised pustular psoriasisPustular psoriasisPsoriasis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical Group
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesNanjing Shunxin Pharmaceuticals Co Ltd Of Chiatai Tianqing Pharmaceutical GroupJiangsu Chia Tai-Tianqing Pharmaceutical Co Ltd
Inactive CompaniesN/A
Active IndicationsGeneralised pustular psoriasisPustular psoriasisPsoriasis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A